Capricor Therapeutics enters mid-July with a widening divergence: the small-cap biotech is down 7.7% on the week to $22.22 while closely correlated peers are posting meaningful gains, and the short position is not retreating.
The peer gap is the sharpest new angle this week. GERN added 14.6% over the same five sessions. DYN rose 12.1%. VKTX gained 6.6%. CAPR moved the other way. That relative weakness — a stock declining while its nearest neighbours rally — matters when short interest is already running at 31% of the free float. It signals that CAPR-specific concerns are driving the price action, not a sector-level tide.
Short interest tells a consistent story of sustained accumulation. Bears hold roughly 14.2 million shares, equal to 31% of the free float — up 7.2% on the week and 24% over the past month. The mid-week relief flagged in the July 4 note has reversed cleanly; the July 7 reading shows the position back near its monthly high. The ORTEX short score is 77.3, ranking in just the 6th percentile of the universe, meaning 94% of stocks tracked carry a less bearish short-positioning profile. The month-long accumulation trend remains the dominant signal: this is not a plateau.
The borrow market is the enduring contradiction. Despite a short position that has grown by nearly a quarter in a month, the cost to borrow has actually fallen — down 9% on the week to just 0.54%. Availability is loose at 173%, roughly 29 million shares still available against 14 million currently borrowed. That means entering the short is cheap and straightforward. There is no squeeze pressure in the lending pool, and the cost does not reflect the elevated conviction implied by the 31% float short. Options positioning has edged slightly more defensive — the put/call ratio moved to 0.43 against a 20-day average of 0.38, a modest but notable shift sitting 1.6 standard deviations above recent norms, its highest reading in over a month.
Institutional flows add another layer. Suvretta Capital built a 6.6% stake, Tang Capital added 1.7 million shares to reach 5.9%, and State Street lifted its position by 1.35 million shares — all reported at the March 31 quarter-end. BlackRock added 571,000 shares in a filing as recent as June 30. These are meaningful builds from known active managers, creating a structural tension between institutional buyers and the short sellers pressing the other way. Point72, notably, trimmed by just over a million shares over the same period. The insider picture has not changed: the CFO and General Counsel both sold at $30 in late June, well above the current $22.22, and the 90-day net runs to approximately $8.4 million in sales with no offsetting purchases.
The last earnings print on May 12 saw the stock fall 4.9% the next day and 15.6% over the following five sessions. The next print is scheduled for August 6 — now under four weeks away. With the stock already down 17% in a month, the setup heading into that date will be worth watching: whether the short position continues to build or begins to flatten ahead of the release is the key positioning question, particularly given how loosely priced the borrow currently is relative to the scale of the bear thesis.
See the live data behind this article on ORTEX.
Open CAPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
